DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

Clinical trial NCT05705349 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05705349
Sponsor: Merck Sharp & Dohme LLC
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

HIV-1 Infection

Start date: 2023-03-08
Primary completion: 2025-10-13
Enrollment: 537

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.